Pombo de Oliveira M S, Matutes E, Rani S, Morilla R, Catovsky D
MRC Leukaemia Unit, Royal Postgraduate Medical School, London, UK.
Acta Haematol. 1988;80(2):61-4. doi: 10.1159/000205603.
The expression of two myeloid antigens identified by the monoclonal antibodies (McAb) MCS2 (CD13) and MY9 (CD33) was investigated in 136 cases of leukaemia. MCS2 was positive in blast cells of 78 of 88 (88.5%) and MY9 in 51 of 81 (64%) cases of acute myeloid leukaemia (AML) and chronic granulocytic leukaemia in myeloid blast crisis. One or other McAb, or both, were positive in all but 2 (2.3%) of these cases. MCS2 was more sensitive than MY9 to detect blasts of the myeloid lineage due to its most frequent reactivity in the cytoplasm of fixed cells by the immunoperoxidase (IP) technique compared with its membrane expression on cell suspensions by immunofluorescence (IF). MY9 was not suitable for tests on fixed cells. MCS2 was positive by IP but not by IF in 24% of AML, but the reverse was not observed. This suggests that the antigen detected by MCS2 is expressed in myeloblasts first in the cytoplasm and later on the cell membrane, pattern which is similar to that of the early antigens CD3 and CD22 in T and B lineage lymphoblasts, respectively. MCS2 was always positive in FAB types of AML-involving myeloblasts (M1-M4), including cases of undifferentiated morphology (M0), whilst MY9 was more frequently positive in monocytic leukaemia (M5). On the other hand, MCS2 was positive in 4 of 33 cases of acute lymphoblastic leukaemia and MY9 in 1. We conclude that both McAb, particularly MCS2, contribute to the better characterisation of myeloid leukaemias but that other tests are required to clarify the nature of the blasts when unexpected reactivities are observed.
采用单克隆抗体（McAb）MCS2（CD13）和MY9（CD33）鉴定的两种髓系抗原的表达情况在136例白血病患者中进行了研究。在88例急性髓系白血病（AML）和慢性粒细胞白血病髓系原始细胞危象患者中，88例中的78例（88.5%）原始细胞MCS2呈阳性，81例中的51例（64%）MY9呈阳性。除2例（2.3%）外，所有这些病例中一种或另一种McAb或两者均呈阳性。由于与免疫荧光（IF）在细胞悬液上的膜表达相比，免疫过氧化物酶（IP）技术在固定细胞的细胞质中反应更频繁，MCS2比MY9检测髓系谱系原始细胞更敏感。MY9不适合对固定细胞进行检测。24%的AML患者中MCS2通过IP呈阳性但通过IF呈阴性，但未观察到相反情况。这表明MCS2检测到的抗原首先在细胞质中表达，随后在细胞膜上表达，这种模式分别类似于T和B谱系淋巴母细胞中早期抗原CD3和CD22的表达模式。MCS2在FAB分型涉及原始粒细胞的AML（M1 - M4）中总是呈阳性，包括形态未分化的病例（M0），而MY9在单核细胞白血病（M5）中更常呈阳性。另一方面，33例急性淋巴细胞白血病中有4例MCS2呈阳性，1例MY9呈阳性。我们得出结论，两种McAb，尤其是MCS2，有助于更好地鉴定髓系白血病，但当观察到意外反应性时，需要其他检测来明确原始细胞的性质。
